EPAM Systems Inc vs IDEXX Laboratories, Inc. — how do they compare? EPAM Systems Inc trades at $112.92 (market cap $5.87B), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 6.9× EPAM Systems Inc's market cap, and EPAM Systems Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold EPAM Systems Inc for 37 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| EPAM | IDXX | |
|---|---|---|
Market Cap | $5.87B | $40.43B |
Volume | 847,420 | 692,164 |
Sector | Technology | Health |
52-Week High | $221.40 | $766.68 |
52-Week Low | $76.04 | $504.70 |
Typical Hold Time | 37 Days | 46 Days |
Enterprise Value | $5.24B | $41.32B |
Signals from Pluang's Aura AI — not financial advice
EPAM Systems trades at $113.24, up 4.54% today, reflecting strong momentum. The stock shows a bullish technical trend, trading near resistance at $115. Fundamentally, EPAM reported Q2 2026 EPS of $3.38, beating estimates, with revenue reaching $5.46B in 2025. Recent news highlights a partnership with Wiz for cloud security and activist investor Engine Capital urging share buybacks, signaling confidence in undervaluation.
The outlook is positive, supported by a consensus price target of $119 and strong analyst buy ratings (59.46%). However, risks include slower North American growth and AI disruption to legacy services. The stock presents a value opportunity with a P/E of 15.45, but investors should monitor execution on AI-native revenue growth and margin sustainability.
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →